RNA, U2 small nuclear 30, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-30P profile across patient tissues and cancer cell-line models. RNU2-30P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RNU2-30P is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, RNU2-30P RNA expression shows 6,324 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and HNSC as cancer lineages where RNU2-30P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-30P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-30P survival associations across molecular data types. RNU2-30P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-30P RNA expression–survival associations across cancer types. High RNU2-30P expression shows unfavorable associations in THYM, READ and DLBC, but favorable associations in STAD, BLCA and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for RNU2-30P RNA expression.
This table summarizes RNU2-30P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-30P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-30P shows higher tumor expression in HNSC and LUAD. The HNSC box plot shows higher RNU2-30P RNA expression in tumor versus normal tissue (log2 FC = +0.093, t-test p = .022).
This table shows molecular features associated with RNU2-30P in patient tissues and cancer cell lines. In patient samples, RNU2-30P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
